Welcome to our dedicated page for Amylyx Pharmaceuticals SEC filings (Ticker: AMLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. For a clinical-stage biopharmaceutical issuer focused on neurodegenerative and endocrine diseases, these documents are a primary source of information on financial condition, capital raising, and material program decisions.
Current reports on Form 8-K are especially relevant for AMLX. Recent 8-K filings have covered quarterly financial results, underwritten public offerings of common stock, and key R&D updates such as the decision to discontinue the ORION program of AMX0035 in progressive supranuclear palsy after Phase 2b results did not show differences versus placebo. Other 8-Ks describe the entry into underwriting agreements for equity offerings and the intended use of proceeds, including avexitide commercial readiness, research and development, working capital, and other general corporate purposes.
Investors can also use this page to track registration statements and prospectus supplements referenced in 8-Ks, which outline the terms of offerings and the securities being issued, as well as ongoing reporting obligations that detail research and development focus, cash runway expectations, and risk factors tied to Amylyx’ pipeline programs.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points from lengthy documents, helping users quickly understand items such as results of operations, material program changes, or capital structure updates. Real-time ingestion from the SEC’s EDGAR system means new Amylyx filings, including 8-Ks and other periodic reports, appear promptly, while structured views of exhibits and key sections make it easier to locate information on topics like avexitide development, AMX0035, AMX0114, and AMX0318.
For those analyzing AMLX stock, this page serves as a focused hub for reviewing the company’s regulatory record, understanding how it communicates material events, and seeing how financing activities align with its clinical-stage strategy.
Amylyx Pharmaceuticals reported a key setback in its neurology pipeline. The company is discontinuing the ORION program of AMX0035 (sodium phenylbutyrate and taurursodiol) in adults living with progressive supranuclear palsy after the treatment did not show differences compared to placebo on primary or secondary outcomes at Week 24.
As a result, Amylyx will stop the ongoing Phase 2b trial and its open-label extension and will not start the planned Phase 3 portion of the program. The company noted that safety data in this study were consistent with safety data from prior AMX0035 studies, indicating no new safety concerns despite the lack of efficacy in this indication.
Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals (AMLX), reported two Rule 10b5-1 sales totaling 30,000 common shares on August 12, 2025 and August 13, 2025. The August 12 sales comprised 15,000 shares at a weighted average price of $8.0735 (trades ranged $7.82–$8.27) and the August 13 sales comprised 15,000 shares at a weighted average price of $8.3364 (trades ranged $8.13–$8.47). After these transactions the reporting person beneficially owned 156,969 shares. The sales were executed under a 10b5-1 trading plan adopted on May 13, 2025. The Form 4 was filed and signed by an attorney in fact on August 14, 2025.
Amylyx Pharmaceuticals (AMLX) filed a Form 144 reporting a proposed sale of 30,000 common shares through Morgan Stanley Smith Barney LLC Executive Financial Services. The filing lists an aggregate market value of $234,600, an approximate sale date of 08/12/2025, and that the shares trade on NASDAQ. The filing reports 89,167,432 shares outstanding, meaning the 30,000-share notice represents approximately 0.034% of outstanding shares.
The securities were acquired as Restricted Stock Units from the issuer on 09/30/2024 and paid on that date. The filing reports "Nothing to Report" for securities sold in the past three months. Some standard Form 144 attestation language about material nonpublic information and Rule 10b5-1 is present, while several filer and issuer identification fields in the form appear blank or not provided.
Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports shared beneficial ownership of 8,800,000 shares of Amylyx Pharmaceuticals, Inc. ("AMLX"). Those shares represent 9.87% of the company's common stock, based on an aggregate of 89,141,087 shares outstanding as of April 28, 2025. The holding is reported as shared voting and shared dispositive power of 8,800,000 shares, with 0 shares of sole voting or sole dispositive power.
The filing is submitted on Schedule 13G/A and includes a certification that the securities were acquired and are held in the ordinary course of business and not to influence control of the issuer.
Key disclosure: On 24 June 2025 Point72 Asset Management, Point72 Capital Advisors and founder Steven A. Cohen jointly filed a Schedule 13G regarding Amylyx Pharmaceuticals, Inc. (AMLX).
The filing shows 4,717,709 AMLX common shares held through Point72 Associates, equivalent to 5.3 % of the company’s outstanding stock. All voting and dispositive authority is listed as “shared,” with zero sole power reported. The report is passive, made under Rule 13d-1(b), and classifies the reporting persons as: Point72 Asset Management – “PN” (Partnership), Point72 Capital Advisors – “CO” (Corporation), and Mr. Cohen – “IN” (Individual).
Ownership is indirect: Point72 Asset Management manages the securities, Point72 Capital Advisors is its general partner, and Mr. Cohen controls both entities. The principal business address for all parties is 72 Cummings Point Road, Stamford, CT 06902. A joint-filing agreement (Exhibit 99.1) formalises combined reporting.
This disclosure elevates Point72 to the roster of ≥5 % institutional holders of Amylyx, giving the hedge fund material visibility in the share register; however, the filing contains no purchase prices, transaction timetables, or stated strategic intentions beyond passive investment.